Related Experiment Video

Updated: Mar 14, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.8K

Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs

Åke Sjöholm1

  • 1Karolinska Institutet, Department of Clinical Science and Education, Division of Internal Medicine, Unit for Diabetes Research, Södersjukhuset, SE-118 83 Stockholm, Sweden. ake.sjoholm@sodersjukhuset.se.

Pharmaceuticals (Basel, Switzerland)
|October 8, 2016
PubMed

Insights

Liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, shows promise for type 2 diabetes management. Clinical trials indicate significant improvements in glycaemic control, weight reduction, and low hypoglycemia risk.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Current type 2 diabetes treatments often fail to prevent disease progression and achieve optimal glycemic control.
  • Existing therapies may lead to undesirable side effects such as weight gain and hypoglycemia.
  • There is a significant unmet need for novel antidiabetic agents that address these limitations.

Approach:

  • Liraglutide, a human glucagon-like peptide-1 (GLP-1) analogue, was developed to leverage the therapeutic potential of GLP-1.
  • Liraglutide shares high sequence identity (97%) with native GLP-1, mimicking its physiological actions.
  • The efficacy and safety of liraglutide were evaluated in the phase 3 Liraglutide Effect and Action in Diabetes (LEAD) trial program.

Key Points:

  • Liraglutide treatment demonstrated substantial improvements in glycemic control in patients with type 2 diabetes.
  • The therapy was associated with a low risk of hypoglycemia, a common concern with other antidiabetic drugs.
  • Patients treated with liraglutide experienced reductions in body weight and systolic blood pressure.
  • Emerging evidence suggests liraglutide may enhance beta-cell function and potentially increase beta-cell mass.

Conclusions:

  • Liraglutide represents a promising new therapeutic option for type 2 diabetes.
  • This GLP-1 analogue may overcome limitations of current treatments, addressing critical unmet clinical needs.
  • Further research into liraglutide's effects on beta-cell function and mass could offer new insights into diabetes management.
Keywords:
GLP-1LEADglycaemic controlliraglutidetype 2 diabetes

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

667
Multidisciplinary Approach to Obesity Management: A Case Report05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.4K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.0K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
804
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
860
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.3K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K